|
|
||||||||
RESEARCH AND PRACTICE |
Kristina M. Zierold is with the Department of Environmental Health Sciences, Arnold School of Public Health, University of South Carolina, Columbia. Lynda Knobeloch and Henry Anderson are with the Wisconsin Division of Public Health, Bureau of Environmental Health, Madison.
Correspondence: Requests for reprints should be sent to Kristina M. Zierold, PhD, Department of Environmental Health Sciences, Arnold School of Public Health, 800 Sumter St, University of South Carolina, Columbia, SC 29208 (e-mail: zierold{at}gwm.sc.edu).
| ABSTRACT |
|---|
|
|
|---|
Inorganic arsenic is naturally occurring in groundwaters throughout the United States. This study investigated arsenic exposure and self-report of 9 chronic diseases. We received private well-water samples and questionnaires from 1185 people who reported drinking their water for 20 or more years. Respondents with arsenic levels of 2 µg/L or greater were statistically more likely to report a history of depression, high blood pressure, circulatory problems, and bypass surgery than were respondents with arsenic concentrations less than 2 µg/L.
| INTRODUCTION |
|---|
|
|
|---|
Many studies have documented associations between arsenic exposure and chronic illness; however, most have focused on high exposures and cancers.2,4,5,1315 Less studied have been the effects of low-level arsenic exposure.
In 1987, a groundwater study conducted by the Wisconsin Department of Natural Resources identified arsenic in groundwater above the maximum contaminant level coincident with a bedrock layer at the interface of the St. Peter Sandstone and Sinnippee Dolomite. The geologic formation exists beneath more than 20 000 private water supply wells throughout several Wisconsin counties. Water samples collected from 1943 private wells between 1992 and 1993 contained arsenic concentrations that ranged from less than 2 µg/L to 12 000 µg/L. Nearly 20% of the water samples contained concentrations that exceeded the new federal drinking water standard of 10µg/L.16
The principal objective of this research was to evaluate the prevalence of 9 different chronic diseases in adults who drink water from privately owned wells in the at-risk area.
| METHODS |
|---|
|
|
|---|
At the completion of the awareness campaign (approximately 1 month after all samples were returned), homeowners were invited to an informational meeting at the local town hall. During this meeting, they received the results of their well-water tests and were given the opportunity to ask state experts questions.
Data from the surveys were analyzed with SAS, Version 8.2 (SAS Institute Inc, Cary, NC). Arsenic water concentrations were grouped into 3 strata (< 2 µg/L, 210 µg/L, > 10 µg/L). Analysis was limited to those aged 35 years or older who reported drinking their well water for 20 or more years. To evaluate the magnitude of any association between arsenic water concentrations and chronic disease status, multivariate logistic regression was used to calculate adjusted odds ratios (ORs) and 95% confidence intervals (CIs).
| RESULTS |
|---|
|
|
|---|
The results of the logistic regression analysis are shown in Table 1
. Individuals with wells in the mid strata of arsenic concentrations (between 2 µg/L and 10 µg/L) were significantly more likely to report having depression than were respondents in the lowest strata (arsenic concentrations < 2 µg/L) (adjusted OR = 2.74; 95% CI = 1.14, 6.63). Additionally, respondents with well-water arsenic concentrations greater than 10 µg/L were significantly more likely to report having had cardiac bypass surgery, high blood pressure, and circulatory problems than were respondents whose well water had arsenic concentrations less than 2µg/L.
|
| DISCUSSION |
|---|
|
|
|---|
Caution in interpretation of our results is warranted because the health data are self-reported and not verified by medical record review. Also, we did not know the arsenic levels in the homeowners drinking water over the entire period of more than 20 years or how much arsenic was actually ingested. We assumed that our arsenic water concentration strata assignment was a reasonable surrogate for exposure and would have remained constant over the period. The possibility of other co-minerals and metals in the water samples contributing to health outcomes was not evaluated.
| Footnotes |
|---|
Contributors
K. M. Zierold conducted the analyses and led the writing of the brief. L. Knobeloch conceived the study and supervised its implementation. H. Anderson assisted with the study and the analysis. All authors helped to conceptualize ideas, interpret findings, and review and edit drafts of the brief.
Human Participant Protection
No protocol approval was needed for this study.
Accepted for publication November 11, 2003.
| References |
|---|
|
|
|---|
2. Chiou HY, Hsueh YM, Liaw KF, et al. Incidence of internal cancers and ingested inorganic arsenic: a seven-year follow-up study in Taiwan. Cancer Res.1995;55:12961300.
3. Tsuda T, Babazono A, Yamamoto E, et al. Ingested arsenic and internal cancer: a historical cohort study followed for 33 years. Am J Epidemiol.1995; 141:198209.
4. Wu MM, Kuo TL, Hwang YH, Chen CJ. Dose-response relation between arsenic concentration in well water and mortality from cancers and vascular diseases. Am J Epidemiol.1989;130:11231132.
5. Tseng WP, Chen WY, Sung JL, Chen JS. A clinical study of Blackfoot disease in Taiwan: an epidemic of peripheral vascular disease. Memoirs Coll Med Natl Taiwan Univ. 1961;7:118.
6. Engel RR, Hopenhayn-Rich C, Receveur O, et al. Vascular effects of chronic arsenic exposure: a review. Epidemiol Rev.1994;16:184209.
7. Engel RR, Smith AH. Arsenic in drinking water and mortality from vascular disease: an ecologic analysis in 30 counties in the United States. Arch Environ Health.1994;49:418427.[Web of Science][Medline]
8. Hertz-Picciotto I, Arrighi HM, Hu SW. Does arsenic exposure increase the risk for circulatory disease? Am J Epidemiol. 2000;151:174181.
9. Donofrio PD, Wilbourn AJ, Albers JW, Rogers L, Salanga V, Greenberg HS. Acute arsenic intoxication presenting as Guillain-Barre-like syndrome. Muscle Nerve.1987;10:114120.[Web of Science][Medline]
10. Murphy MJ, Lyon LW, Taylor JW. Subacute arsenic neuropathy: clinical and electrophysiological observations. J Neurol Neurosurg Psychiatry.1981;44: 896900.
11. Lai MS, Hsueh YM, Chen CJ, et al. Ingested inorganic arsenic and prevalence of diabetes mellitus. Am J Epidemiol.1994;139:484492.
12. Rahman M, Axelson O. Diabetes mellitus and arsenic exposure: a second look at case-control data from a Swedish copper smelter. Occup Environ Med.1995; 52:773774.
13. Borzsonyi M, Berecski A, Rudnai P, Sanady MC, Horvath A. Epidemiological studies on human subjects exposed to arsenic in drinking water in southeast Hungary. Arch Toxicol.1992;66:7778.[Web of Science][Medline]
14. Cebrian ME, Albores A, Aquilar M, Blakely E. Chronic arsenic poisoning in the North of Mexico. Hum Toxicol.1983;2:121133.[Web of Science][Medline]
15. Chakraborty AK, Saha KC. Arsenical dermatosis from tubewell water in West Bengal. Indian J Med Res.1987;85:326334.[Web of Science][Medline]
16. Stoll R, Burkell R, La Plant N. Naturally-Occurring Arsenic in Sandstone Aquifer Water Supply Wells of NE Wisconsin. Madison: Wisconsin Department of Natural Resources; 1995. WI Groundwater Research and Monitoring Project Summaries. Publication WI DNR PUBL-WR-423-95.
17. Agency for Toxic Substances and Disease Registry (ATSDR). Toxicological Profile for Arsenic. Atlanta, Ga: US Dept of Health and Human Services, Public Health Service; 2000.
18. Calderon J, Navarro ME, Jimenez-Capdeville ME, et al. Exposure to arsenic and lead and neuropsychological development in Mexican children. Environ Res.2001;85:6976.[Medline]
19. Danan M, Dally S, Conso F. Arsenic-induced encephalopathy. Neurology.1984;34:1524.
20. Saha JC, Diskshit AK, Bandyopadhyay M. A review of arsenic poisoning and its effects on human health. Crit Rev Environ Sci Technol.1999;29: 281313.
This article has been cited by other articles:
![]() |
J. C. States, S. Srivastava, Y. Chen, and A. Barchowsky Arsenic and Cardiovascular Disease Toxicol. Sci., February 1, 2009; 107(2): 312 - 323. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Navas-Acien, E. K. Silbergeld, R. Pastor-Barriuso, and E. Guallar Arsenic Exposure and Prevalence of Type 2 Diabetes in US Adults JAMA, August 20, 2008; 300(7): 814 - 822. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Maharjan, C. Watanabe, S. A. Ahmad, M. Umezaki, and R. Ohtsuka Mutual interaction between nutritional status and chronic arsenic toxicity due to groundwater contamination in an area of Terai, lowland Nepal J Epidemiol Community Health, May 1, 2007; 61(5): 389 - 394. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Chen, P. Factor-Litvak, G. R. Howe, J. H. Graziano, P. Brandt-Rauf, F. Parvez, A. van Geen, and H. Ahsan Arsenic Exposure from Drinking Water, Dietary Intakes of B Vitamins and Folate, and Risk of High Blood Pressure in Bangladesh: A Population-based, Cross-sectional Study Am. J. Epidemiol., March 1, 2007; 165(5): 541 - 552. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Desheng and Z. Niya Effect of Arsanilic Acid on Performance and Residual of Arsenic in Tissue of Japanese Laying Quail Poult. Sci., December 1, 2006; 85(12): 2097 - 2100. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Ross RE: "CIGARETTE SMOKING AND INCIDENCE OF FIRST DEPRESSIVE EPISODE: AN 11-YEAR, POPULATION-BASED FOLLOW-UP STUDY" Am. J. Epidemiol., November 1, 2006; 164(9): 917 - 918. [Full Text] [PDF] |
||||
![]() |
A. Navas-Acien, A. R. Sharrett, E. K. Silbergeld, B. S. Schwartz, K. E. Nachman, T. A. Burke, and E. Guallar Arsenic Exposure and Cardiovascular Disease: A Systematic Review of the Epidemiologic Evidence Am. J. Epidemiol., December 1, 2005; 162(11): 1037 - 1049. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Archer, K. A. Hudson-Edwards, D. A. Preston, R. J. Howarth, and K. Linge Aqueous exposure and uptake of arsenic by riverside communities affected by mining contamination in the Rio Pilcomayo basin, Bolivia Mineralogical Magazine, October 1, 2005; 69(5): 719 - 736. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |